



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

SJ

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/696,684	10/29/2003	Joseph F. Dellaria	57071US040	5265
32692	7590	05/05/2004	EXAMINER	
3M INNOVATIVE PROPERTIES COMPANY PO BOX 33427 ST. PAUL, MN 55133-3427		HUANG, EVELYN MEI		
		ART UNIT		PAPER NUMBER
		1625		

DATE MAILED: 05/05/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/696,684	DELLARIA ET AL.
	Examiner	Art Unit
	Evelyn Huang	1625

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
 2a) This action is **FINAL**. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 22,26 and 31-35 is/are pending in the application.
 4a) Of the above claim(s) 33 and 34 is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 22,26,31,32 and 35 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
 Paper No(s)/Mail Date _____.
- 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____.
 5) Notice of Informal Patent Application (PTO-152)
 6) Other: _____.

Art Unit: 1625

DETAILED ACTION

1. Claims 22, 26, 31-35 are pending. Claims 1-21, 23-25, 27-30 have been canceled according to the preliminary amendment filed on 10-29-2003.

Election/Restrictions

2. Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 22, 26, 31, 32, 35 drawn to a method of treating a neoplastic disease with the compound of formula I, II, or a compound of claim 32.
- II. Claim 33, drawn to a method of inducing cytokine biosynthesis with 2-butyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine.
- III. Claim 34, drawn to a method of treating a viral disease with 2-butyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine.

The inventions are distinct, each from the other because of the following reasons: these groups are drawn to different method of use with compounds of different scope. Group I is drawn to a method of treating a neoplastic disease with the compound of formula I, II, or a compound of claim 32. Group II is drawn to a method of inducing cytokine biosynthesis. Group III is drawn to a method of treating a viral disease. They have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Group II or III, restriction for examination purposes as indicated is proper.

3. During a telephone conversation with Mr. Ersfeld on 4-30-2004 a provisional election was made with traverse to prosecute the invention of Group I, claims 22, 26, 32, 32, 35. Affirmation of this election must be made by applicant in replying to this Office action. Claims

Art Unit: 1625

33, 34 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Claim Rejections - 35 USC § 112

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 22, 26, 31, 33-35 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. ***.

a. *Nature of the invention.*

The instant invention is drawn to a thioether substituted imidazoquinoline for inducing cytokine biosynthesis in an animal.

b. *State of the prior art and the level of the skill in the art.*

Imidazo[4,5-c]quinolin-4-amine derivatives are known (Gerster I, 5266575, PTO-1449, columns 9-10). Certain imidazo[4,5-c] quinoline compounds have been shown to induce TNF and IL-1 production (Testerman, PTO-1449, abstract). Although interferon alpha has been implicated in many diseases, including neoplastic diseases, a nexus between the induction of interferon biosynthesis and the treatment of these diseases has not been fully established. Furthermore, at present there is no known umbrella drug that can treat any type of neoplastic

Art Unit: 1625

diseases, since the different neoplastic diseases are of different origins, have different cellular mechanisms and consequently, would require different treatment protocols.

The level of the skill in the anticancer art is high.

c. *Predictability/unpredictability of the art.*

The high degree of unpredictability is well-recognized in the anticancer art. For example, some drugs known to be effective against small cell lung cancer are inactive in melanoma (Sof'ina et al. Experimental Evaluation of Antitumor Drugs in the USA and USSR and Clinical Correlations. NCI Monograph 55. NIH Publication No. 80-1933 (1980), page 77). The 1, 3-cyclohexanediones shown to be active in test against human sarcoma is found to be inactive against other types of cancer such as leukemia, lymphosarcoma etc. (Strandtmann, J. Med. Chem. (1967), 10(6):1063-1065). Correlation between the anti-tumor drugs in experimental system and in patient treatment is incomplete (Sof'ina, page 76). Furthermore, it is known that a slight change in the structure of the compound would drastically change its biological activity as evidenced in the very different ED₅₀ values for the structurally similar compounds (Strandtmann, page 1065, Table II). One of ordinary skill in the art therefore would have little basis to extrapolate the data from one set of compounds to other structurally dissimilar compounds.

d. *Amount of guidance/working examples.*

The preparation of the inventive compound has been described (Example 236). The ability of the example compounds to induce interferon and TNF in human blood cells is shown in the specification. The procedures for assessment of the anti-viral or anti-neoplastic activity are not described. No in vivo procedures are described.

e. *Breadth of the claims.*

Applicant's assertion that all the structurally diverse compounds embraced by instant claims 22, 31, including those having aryl, heteroaryl, heterocyclyl, further substituted with optionally substituted aryl, heteroaryl, heterocyclyl, or the compounds of claim 26, are effective in treating any or all neoplastic diseases does not commensurate with the scope of the objective enablement, especially in view of the high degree of unpredictability in the anti-cancer art, the working examples limiting to induction of interferon alpha and TNF, and the fact that at present there is no known umbrella drug effective for treating any or all types of neoplastic diseases (paragraphs c, d above).

f. *Quantitation of undue experimentation.*

Since insufficient guidance and teaching have been provided by the specification (paragraphs c-e above), one of ordinary skill in the art, even with high level of skill, is unable to use the instant compound as claimed without undue experimentation.

Double Patenting

6. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

7. Claims 22, 26, 31, 32, 35 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-12, 17-24, 29-34 of U.S. Patent No. 6664264. The compound of instant claim 32 is a species encompassed by the patented generic compound claims 1-11, and is specifically claimed in the patented species claim 12 (column 45, lines 66-67). The patented method comprising administering the patented compound to the animal having a neoplastic disease is embraced by the instant method of treating a neoplastic disease with the same compound.

8. Claims 22, 26, 31, 32, 35 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-11, 23, 24-27, 33-35, 40-45 of U. S. Patent No. 6667312.

Art Unit: 1625

The 2-butyl compound of instant claim 32 is a species encompassed by the patented generic compound claims 1-11, and is the next adjacent homolog of the 2-propyl (first compound) of the species claim 23 (column 96, lines 5-6). The patented compound suggests the instant. Furthermore, butyl and propyl are within the meaning of alkyl as 2-substituent in the generic claims. One of ordinary skill in the art would be motivated to prepare the next adjacent homolog of the patented species compound to arrive at the instant with the reasonable expectation of obtaining an additional cytokine biosynthesis-inducing compound.

The patented method comprising administering the patented compound to the animal having a neoplastic disease is embraced by the instant method of treating a neoplastic disease with the same compound.

9. Claims 22, 26, 31, 32, 35 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 30, 39, 44, 49, 52 of copending Application No. 10/696477.

The copending method of treating a neoplastic disease comprising administering to an animal in need thereof, the compound wherein n=0, or the species compound of claim 44, is encompassed by the instant method.

The compound of instant claim 32 has a 2-butyl-1-(methansulfonyl-pentyl) whereas the copending compound has a 2-ethyl-1(methylsulfonyl-ethyl). However, butyl and ethyl, pentyl and ethyl are optional choices within the meaning of alkyl substituent as defined in the copending generic claims, and are exemplified in the compounds of copending claim 44. One of ordinary skill in the art would therefore be motivated to modify the copending compound with the alternative alkyl substituents to arrive at the instant with the reasonable expectation of obtaining an additional cytokine biosynthesis-inducing compound.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Conclusion

10. No claims are allowed.

Art Unit: 1625

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Evelyn Huang whose telephone number is 571-272-0686. The examiner can normally be reached on Tuesday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Evelyn Huang

Primary Examiner

Art Unit 1625